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Abstract
Background: There is large variation in the therapeutic response to inhaled corticosteroids (ICS) in COPD patients.
We present a pooled analysis of our previous studies investigating the effects of corticosteroids on lung
macrophages, in order to robustly determine whether corticosteroid sensitivity in COPD cells is reduced compared
to controls, and also to evaluate the degree of between individual variation in drug response.
Methods: Data from 20 never smokers (NS), 27 smokers (S) and 45 COPD patients was used. Lung macropahges
had been stimulated with lipopolysaccharide (LPS), with or without the corticosteroid dexamethasone, and tumour
necrosis factor (TNF)-α, interleukin (IL)-6 and chemokine C-X-C motif ligand (CXCL) 8 production was measured.
Results: There was no difference in the anti-inflammatory effects of corticosteroids when comparing group mean
data of COPD patients versus controls. The inhibition of TNF-α and IL-6 was greater than CXCL8. The effects of
corticosteroids varied considerably between subjects, particularly at lower corticosteroid concentrations.
Conclusions: We confirm that overall corticosteroid sensitivity in COPD lung macrophages is not reduced
compared to controls. The varied effect of corticosteroids between subjects suggests that some individuals have an
inherently poor corticosteroid response. The limited suppression of lung macrophage derived CXCL8 may promote
neutrophilic inflammation in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terised by an abnormal immune response to inhaled nox-
ious particles, most commonly tobacco smoke [1].
Inflammatory cell numbers including macrophages, neu-
trophils and lymphocytes are increased in the lungs of
COPD patients [2]. These cells secrete a range of inflam-
matory mediators including cytokines, chemokines, prote-
ases and oxidants that contribute to the pathophysiology
of COPD [3, 4].
Inhaled corticosteroids (ICS) are anti-inflammatory
drugs that are commonly used to treat COPD. Cortico-
steroids bind to and activate the glucocorticoid receptor
(GR) [5], resulting in GR nuclear translocation and the
subsequent transrepression of inflammatory gene tran-
scription by inhibition of the activity of transcription
factors such as nuclear factor kappa-light-chain-enhan-
cer of activated B cells (NF-κB) [6].
Initial clinical studies of ICS in COPD showed no long
term benefit of these drugs in unselected patients [7–9].
However, further clinical trials showed that ICS are ef-
fective in the subgroup of COPD patients with a history
of exacerbations, and their efficacy is maximised when
administered with a long acting beta agonist (LABA)
[10, 11]. Furthermore, there is also evidence that COPD
patients with sputum eosinophilia have a greater lung
function response to corticosteroids [12, 13]. There are
clinical concerns about the long term safety of ICS, as
these drugs cause side effects such as osteoporosis, skin
thinning and pneumonia [14]. The therapeutic index of
ICS can be optimised by using these drugs in discrete
subgroups of patients most likely to show a beneficial
clinical response.
It has been reported that corticosteroids have reduced
effects on lung macrophage cytokine production from
COPD patients compared to controls [15, 16]. We have
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failed to reproduce this observation in seven different
studies [17–23]. The reason for the contrasting results
between studies is unclear. The sample sizes of these
previous studies from ourselves and others have often
been limited, perhaps causing false positive or false
negative results. However, we have consistently shown
that the effects of corticosteroids vary between cyto-
kines, with CXCL8 production from both COPD and
control macrophages showing reduced corticosteroid
sensitivity compared to other cytokines.
This paper presents a pooled analysis of our previous
results concerning the effects of corticosteroids on cyto-
kine production from COPD and control lung macro-
phages, in order to overcome potential issues with
limited sample sizes. There were two main objectives;
(1) to compare the group average results from COPD
patients and controls and (2) to determine the degree of
between subject heterogeneity in the in-vitro response to
corticosteroids in COPD patients. In clinical practice, it
is known that the therapeutic response to corticosteroids
varies between patients, and we have studied whether




We have published seven studies that have investigated
the corticosteroid sensitivity of COPD lung macrophages
[17–23]. Five of these studies used the same cell culture
methodology, and studied full drug concentration re-
sponse curves; data from these five studies were used in
this analysis [18–21, 23]. The other two studies were not
included as one study used a different cell culture
incubation time [17] while the other used a single cortico-
steroid concentration [22]. The results from 20 never
smokers (NS), 27 smokers (S) and 45 COPD patients who
participated in previously published studies were used; the
demography of these participants is shown in Table 1.
Cells from the same participants had occasionally been
cultured on two occasions, the first occasion as fresh cells
and the second occasion after freeze—thaw. The results
were used in two papers; this was most frequent in NS
(n = 8). The main analysis presented in this paper uses
results from fresh cells only.
COPD was diagnosed based on ≥10 pack years smok-
ing history, typical symptoms and airflow obstruction.
COPD patients were mainly GOLD stage II with moder-
ate airflow obstruction, although GOLD I and III pa-
tients were also included. The majority of COPD
patients were current smokers. Southworth et al. Plumb
et al. Lea et al. and Higham et al. [23] used lung macro-
phages isolated from resected lung tissue from patients
undergoing surgical resection for lung cancer, whereas
Armstrong et al. [18] used lung macrophages isolated
from bronchoscopic sampling (bronchoalveolar lavage
[BAL]) from research volunteers who did not have lung
cancer. All previous studies were approved by the local
research ethics committee, and the participants had pro-
vided written informed consent.
Lung macrophage culture
Lung macrophages were isolated from resected lung tissue
and BAL as previously described, and then cultured using
the same cell culture methodology [18, 20]. Additional file 1
outlines the method used for cells which underwent
freeze-thaw. All the studies adhered macrophages over
Table 1 Demographics of the study population
Resection Macrophages Bronchoscopy Macrophages
NS S COPD NS S COPD
n 14 21 35 6 6 10
GOLD I NA NA 6 NA NA 4
GOLD II NA NA 22 NA NA 5
GOLD III NA NA 7 NA NA 1
Age 59.6 (15.1) 69.1 (7.3) 68.0 (7.3) 36.0 (8.9) 43.8 (6.4) 62.1 (8.4)
Sex (M/F) 4/10 9/12 27/8 1/5 3/3 5/5
FEV1 (L) 2.2 (0.7) 2.3 (0.8) 1.9 (0.8) 3.0 (0.8) 3.7 (0.9) 2.0 (0.6)
FEV1 % Predicted 99.4 (19.0) 94.9 (16.6) 63.6 (18.6) 101.5 (13.1) 107.0 (9.0) 74.4 (21.8)
FVC (L) 3.0 (0.9) 3.0 (0.9) 3.2 (0.7) 3.7 (1.2) 4.8 (1.3) 3.3 (1.1)
FEV1/FVC Ratio (%) 76.3 (6.5) 75.2 (4.3) 58.4 (10.5) 81.0 (6.6) 76.7 (5.2) 56.2 (9.9)
Pack Year History 0 43.2 (23.3) 54.9 (26.1) 0 15.9 (8.6) 47.1 (30.2)
Current/ex-smoker 0 10/11 24/11 0 6 7/3
ICS Users 0 0 13 0 0 7
Data shown are mean (sd)
NS never smokers, S smokers, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid
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night before pre-incubating with dexamethasone for
1–2 h, prior to stimulation with lipopolysaccharide
(LPS 1 μg/ml, Escherichia Coli B6-026; Sigma-Aldrich)
for 24 h. We have previously shown that this is a sub-
maximal LPS concentration [17]. Supernatants were
removed and analysed for TNF-α, IL-6 and CXCL8 by
enzyme linked immunosorbant assay (ELISA, R & D
Systems, Abbingdon, UK); the same immunoassays were
used in each study.
Data analysis
All statistical analysis was performed using GraphPad
InStat software (GraphPad Software Inc., La Jolla,
California, USA). Normality of data was assessed by
the Kolmogorov-Smirnoff test. Mean dexamethasone
inhibition of TNF-α, IL-6 and CXCL8 were parametric
and therefore compared using a one-way ANOVA. One
set of results taken from fresh macrophages was in-
cluded per subject for the main analysis. The reproducibil-
ity of the results was analysed by plotting concentration
response curves that had been repeated using fresh lung
macrophages and those which had undergone freeze-thaw
(NS; N = 8). When calculating percentage inhibition,
100 % inhibition was complete inhibition of LPS stimu-
lated release; baseline levels were not subtracted from
these values. Univariate correlations were performed
using the Spearman rank test. IC50 values for dexa-
methasone (the concentration required to cause 50 %
inhibition) were calculated using sigmoidal curve fitting
of group mean data.
Results
Group mean data
Combining the data using fresh cells from our previous
studies, unstimulated and LPS stimulated cytokine levels
are shown in Fig. 1. Unstimulated cytokine levels were
similar between groups. LPS stimulated cytokine pro-
duction was also similar between groups.
We constructed dexamethasone concentration response
curves (Fig. 2). The effect of dexamethasone was not sig-
nificantly different between subject groups (p > 0.05 for all
cytokines at each concentration). We evaluated cortico-
steroid inhibition further by fitting sigmoidal concentra-
tion response curves to the data (Fig. 3). The TNF-α and
IL-6 IC50 values were very similar in the different subject
groups, being in the range 3–10 nM approximately
(Table 2). Corticosteroid inhibition of CXCL8 in NS
failed to reach 50 %, so we could not calculate the IC50.
IC50 values for CXCL8 inhibition in S and COPD pa-
tients were similar (5 nM and 21 nM respectively). In
COPD patients, corticosteroid effects were similar in
current and ex-smokers, patients taking ICS compared
to patients not taking ICS, and males compared to fe-
males (Additional file 2).
The effects of dexamethasone varied between cyto-
kines; the mean inhibition observed at the top of the
concentration response curve for TNF-α and IL-6
was up to 80 %, while for CXCL8 this was below
60 %. In all subject groups, the effect of dexametha-
sone concentrations at the top of the concentration
response curve (e.g. 1000 nM) on TNF-α and IL-6




















































































Fig. 1 Baseline and LPS stimulated cytokine release. The supernatants from the alveolar macrophages of NS, S and COPD patients were untreated
(a-c) or stimulated with LPS (d-f) (1 μg/ml) for 24 h and analysed for TNF-α (a and d), IL-6 (b and e) and CXCL8 (c and f) release. Data shown
are mean ± SEM
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on CXCL8 production (p < 0.01 for all comparisons
in all subject groups).
There were significant correlations (p < 0.001 for all
analyses) for the corticosteroid inhibition of different cy-
tokines in all subject groups (Additional file 3). The r
values for the correlations between cytokines ranged
from 0.54 to 0.9, indicating associations varying from
moderate to strong.
Individual data
The individual dexamethasone concentration response
curves for TNF-α, IL-6 and CXCL8 using fresh cells only
are shown in Fig. 4. Maximal efficacy was achieved at
dexamethasone 100 nM - 1000 nM for the majority of
subjects. The suppression of TNF-α at these concentra-
tions showed relatively little between subject variation in
NS and S, with >60 % inhibition being achieved in most
subjects. There was a slight increase in variation for
TNF-α with COPD patients at 100 nM - 1000 nM, as 3
patients had <60 % inhibition. However, at concentra-
tions <100 nM there were large variations between
COPD patients in the magnitude of TNF-α suppression.
For IL-6 and CXCL8, there was a high degree of vari-
ation between patients in the magnitude of inhibition at
all dexamethasone concentrations. This was particularly
apparent at lower concentrations e.g. at dexamethasone
10 nM the inhibitory effect varied from 0 % to over ap-
proximately 80 %, with this pattern observed in both
COPD patients and controls.
The percentage of subjects who failed to reach >50 %
inhibition by dexamethasone (at any concentration) of
TNF-α was less than 10 % (Additional file 4). Similar
data were observed for IL-6, with less than 10 % of sub-
jects failing to reach 50 % inhibition by dexamethasone.
In contrast, the percentage of subjects who failed to
reach >50 % inhibition of CXCL8 was greater; 35 % in
NS, 21 % in S and 18 % in COPD patients.
Additional file 5 shows that samples isolated from
BAL showed similar results to those from lung resec-
tions. There were 8 NS whose cells had been used on
two occasions. On the first occasion the cells were used
fresh, and on the second occasion the cells had under-
gone freeze-thaw. Additional file 6 shows that the results
of these repeated experiments were very similar.
Discussion
This pooled analysis confirms that the anti-
inflammatory effects of corticosteroids on LPS
a b c























































































Fig. 2 Group mean dexamethasone concentration response curves. The group mean data for dexamethasone inhibition of TNF-α (a), IL-6 (b) and
CXCL8 (c) are shown for never smokers (NS; blue plot), smokers (S; green plot) and COPD patients (red plot). Data shown are mean ± SEM

























































































Fig. 3 Sigmoidal curve fitting of group mean data. The group mean data for dexamethasone inhibition of TNF-α (a), IL-6 (b) and CXCL8 (c) are
shown for never smokers (NS; blue plot), smokers (S; green plot) and COPD patients (red plot)
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stimulated lung macrophages does not differ between
COPD patients and controls when analysing group
mean data. We were also interested to understand the
between subject heterogeneity of corticosteroid effect
on lung macrophages. The individual concentration
response curves showed marked between subject vari-
ation, particularly at the lower corticosteroid concen-
trations. Our results suggest that the overall group
mean sensitivity of lung macrophages to corticoster-
oid treatment is similar in COPD patients and con-
trols, but a proportion of individuals within each
group, including COPD patients, display poor in-vitro
sensitivity to corticosteroids. Perhaps the large be-
tween subject variation observed here for the in-vitro
effects of corticosteroids is relevant to the variable
clinical effects of ICS in COPD patients.
The relatively large sample size used for this pooled
analysis reduces the chance of false positive or negative
results for the group mean data, and supports the con-
cept that the effects of corticosteroids on COPD and
control lung macrophages are similar. The studies in this
pooled analysis all used identical cell culture method-
ology, which is important as different methodology can
alter the effects of corticosteroid sensitivity experiments
through mechanisms such as activation of p38 mitogen
activated protein kinase (MAPK) [23]. This pooled ana-
lysis also confirms that some cytokines, such as TNF-α
and IL-6 show a greater sensitivity to corticosteroid sup-
pression compared to others such as CXCL8. This is
probably highly relevant to the clinical effectiveness of
corticosteroids in COPD patients, as CXCL8 is present
Table 2 IC50 values calculated from sigmoidal curve fitting of
dexamethasone inhibition
TNF-α IL-6 CXCL8
NS S COPD NS S COPD NS S COPD
IC50 (nM) 7.3 3.7 3.4 10.4 9.6 6.2 N/C 5.0 21.0
Data is presented from inhibition of TNF-α, IL-6 and CXCL8 from never smokers
(NS), smokers (S) and COPD patients
N/C not calculated












































































































































































































































































































Dexamethasone (nM) Dexamethasone (nM) Dexamethasone (nM)
Dexamethasone (nM) Dexamethasone (nM) Dexamethasone (nM)
Fig. 4 Individual dexamethasone concentration response curves. The individual concentration response curves for dexamethasone inhibition of
TNF-α (a, b and c), IL-6 (d, e, and f) and CXCL8 (g, h and i) are shown for never smokers (NS; a, d and g), smokers (S; b, e, and h) and COPD
patients (c, f and i)
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in high concentrations in the lungs of COPD patients
[3, 24] and is a key neutrophil chemoattractant [25]. In-
deed, we have previously shown that supernatants from
stimulated COPD lung macrophages cause neutrophil
chemotaxis that is CXCL8 dependent, and that treat-
ment of the lung macrophages with corticosteroids has
little effect on chemotaxis [26].
Although we constructed full corticosteroid concentra-
tion response curves, it could be argued that the higher
concentrations that we studied are clinically less relevant
as low non-molar concentrations of ICS are achieved
within the lungs [27]; up to 0.6 ng per gram of lung tis-
sue of ICS has previously been observed, which is
equivalent to 1.35 nM of drug. We report that the effects
of dexamethasone at concentrations from 0.1 to 10 nM
is extremely heterogeneous with a high degree of be-
tween subject variation, whereas corticosteroid effects at
higher concentrations were more homogeneous, particu-
larly for TNF-α. However, the heterogeneous responses
at the lower concentrations are more likely to reflect the
activity observed in the lungs in real life. At these thera-
peutically achievable concentrations, our results suggest
there is a subgroup of individuals who display relative
corticosteroid insensitivity.
The IC50 values for TNF-α and IL-6 were similar
across the subject groups demonstrating generally simi-
lar corticosteroid sensitivities for these cytokines. How-
ever, due to the limited effects of corticosteroids on
CXCL8 release, we were unable to calculate an IC50
value for NS, which is a limitation of this analysis. Fur-
thermore, the group IC50 values are not reflective of the
wide degree of between individual variation (see Fig. 4)
which shows a subgroup of patients with poor cortico-
steroid sensitivity, particularly at the lower drug
concentrations.
The individual concentration response curves identi-
fied patients who never reached over 50 % inhibition (up
to 35 % of patients for CXCL8). Although this is an arbi-
trary cut-off point, this observation still demonstrates
that in some individuals there is a very limited effect of
corticosteroids on lung macrophages, while in other in-
dividuals the effect is over 80 % inhibition of cytokine
production. Ratcliffe and Dougall reported similar find-
ings with COPD lung macrophages; there was a subset
of patients with a reduced response to corticosteroids
[28]. Similarly, corticosteroids have heterogeneous ef-
fects on alveolar macrophage cytokine production in pa-
tients with asthma [29].
There were significant associations between cytokines
in the magnitude of corticosteroid inhibition; these rela-
tionships were evident in all subject groups. This sug-
gests that low (or high) corticosteroid sensitivity on one
cytokine in an individual is associated with a similar ef-
fect on other cytokines on an individual basis.
There are various possible mechanisms that could be
responsible for the variation in corticosteroid response
between individuals. For example, GR expression deter-
mines the response to corticosteroids [30]. We have pre-
viously shown that the levels of phosphorylated GR in
lung macrophages do not differ between COPD patients
and controls on a group mean basis [20], supporting the
concept that there is no difference in corticosteroid sen-
sitivity between subject groups. However, GR activity
may be determined by the relative expression of GR iso-
forms; whereas GRα is important for mediating the anti-
inflammatory actions of glucocorticoids, GRβ has been
shown to inhibit the activity of GRα [31]. The levels of
GRβ protein have been shown to be increased in BAL
macrophages of steroid insensitive asthmatics compared
to steroid sensitive asthmatics and this corresponds with
reduced nuclear translocation of GRα [32]. More re-
cently it has been shown that the levels of GRβ mRNA
are increased in the peripheral blood neutrophils of
COPD patients compared to healthy subjects [33].
Activation of the p38 MAPK pathway promotes in-
flammation by increasing inflammatory gene expression,
stabilising mRNAs and enhancing protein translation
[34]. Activation of this pathway is corticosteroid insensi-
tive in alveolar macrophages [18], and it has also been
shown that the administration of prednisolone to COPD
patients does not suppress p38 MAPK activation in
whole blood cultured ex vivo [35]. In the current ana-
lysis, it is possible that inflammatory gene expression
in those patients with reduced corticosteroid sensitiv-
ity is associated with increased p38 MAPK activity.
This may be due to increased phosphorylation of GR at
serine 226 by p38 MAPK, which results in reduced nu-
clear translocation and failure of GR to inhibit gene
transcription [36].
A recent study has shown that COPD lung macro-
phages with different densities demonstrate varied cor-
ticosteroid sensitivity [37]. LPS stimulated TNF-α and
CXCL8 secretion from COPD macrophages with a lower
density were less sensitive to corticosteroid inhibition
compared to controls. However, this difference dimin-
ished with increasing macrophage density. The current
analysis used results from unfractionated macrophages,
so we were unable to define the characteristics of cells
from individuals with less corticosteroid sensitivity; indi-
viduals with a higher proportion of corticosteroid in-
sensitive macrophages within a mixed macrophage
population may have a reduced corticosteroid response
overall. Furthermore, it is possible that differences in the
proportions of macrophage subpopulations between
groups may impact the overall group mean corticoster-
oid sensitivities observed.
Lung tissue as far distal to the tumour as possible
from individuals with lung cancer were used, but we
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cannot rule out the possibility that cancer affects macro-
phage phenotype. We have controlled for this to some
extent by the inclusion of macrophages isolated from
BAL from the lungs of subjects who did not suffer from
lung cancer. Additional file 5 shows that the corticoster-
oid response is similar when comparing macrophages
isolated from lung tissue compared to BAL.
The studies included in this analysis used LPS to
stimulate macrophages. The airways of COPD patients
are often colonised with bacteria, making LPS stimula-
tion a physiologically relevant model to study macro-
phage pharmacology [37–39]. Alternatively, other
stimuli such as cigarette smoke extract and IL-1β have
been used as inflammatory stimuli for the purpose of
studying corticosteroid sensitivity in macrophages [15].
The conclusions that we draw from our analysis are rele-
vant only to LPS stimulation of macrophages.
As a secondary analysis, we compared the results
using fresh lung macrophages with those that had
undergone freeze-thaw from the same subject. Cortico-
steroid effects appeared similar, indicating that using fro-
zen cells to study corticosteroid effects is a valid
method.
An important finding of this study is the demonstra-
tion that lung macrophages from a subset of COPD
patients have a high degree of corticosteroid sensitiv-
ity at relatively low concentrations. We could specu-
late that ICS are more likely to exert a clinical benefit
in these patients, but this requires prospective evalu-
ation. Sputum and blood eosinophils have been used
as biomarkers of corticosteroid response [12, 40] in
order to use these drugs in a manner that would opti-
mise the therapeutic index as part of a personalised
medicine regime. It would be interesting to know if
there is a relationship between the lung macrophage
corticosteroid sensitivity reported here and eosinophil
numbers. We did not have the opportunity to study
the detailed clinical characteristics, including eosino-
phil counts, of the COPD patients included in this
analysis, as the majority were undergoing surgery for
lung cancer.
Conclusions
In conclusion, this pooled analysis supports previous ob-
servations that the overall corticosteroid sensitivity of
lung macrophages is not reduced in COPD patients
[17–23]. The effects of corticosteroids on CXCL8 secre-
tion were limited. Interestingly, there was a large vari-
ation between individuals for corticosteroid effects at
lower drug concentrations. These results may be clinic-
ally relevant, as poor suppression of macrophage activity
may result in excessive CXCL8 production promoting
persistent neutrophilic inflammation.
Additional files
Additional file 1: Lung macrophage freeze-thaw method.
(DOCX 13 kb)
Additional file 2: Mean dexamethasone dose response curves
comparing COPD current smokers to ex-smokers, ICS users to those
not using ICS, and males to females. Data from COPD patients was
separated into current smokers (purple plot) vs ex-smokers (grey plot)
(a, b and c), ICS users (black plot) vs those not using ICS (orange plot)
(d, e and f) and male (brown plot) vs female (pink plot) patients (g, h and i).
Supernatants were analysed for TNF-α (a, d and g), IL-6 (b, e, and h) and
CXCL8 (c, f and i). Data shown are mean ± SEM. (PPTX 684 kb)
Additional file 3: Correlations of corticosteroid cytokine inhibition.
Correleations were made between TNF-α and IL-6 (a–c), TNF-α and
CXCL8 (d–f) and IL-6 and CXCL8 (g–i) release from NS (a, d and g), S
(b, e, and h) and COPD patients (c, f and i). Data shown are individual data
points where r represents the Spearman Rank coefficient. (PPTX 895 kb)
Additional file 4: The proportion of subjects who displayed less
than 50 % or 60 % dexamethasone inhibition of LPS stimulated
cytokine production. Data presented as % of subjects for TNF-α
(NS = 20; S = 27; COPD = 45), IL-6 (NS = 18; S = 19; COPD = 31), and CXCL8
(NS = 14; S = 19; COPD = 40). (DOCX 14 kb)
Additional file 5: Individual dexamethasone dose response curves
of macrophages isolated from resected lung tissue and BAL.
Macrophages were isolated from resected lung tissue (black plots) and
BAL (red plots) of never smokers (NS; a, d and g), smokers (S; b, e, and h)
and COPD patients (c, f and i). Supernatants were analysed for TNF-α
(a, b and c), IL-6 (d, e, and f) and CXCL8 (g, h and i). (PPTX 1404 kb)
Additional file 6: Reproducibility of dexamethasone concentration
response curves. Lung macrophages from 8 NS were used on two
separate occasions – experiment 1 (grey circles) and experiment 2 (black
triangles). Dexamethasone concentration response curves are shown for
TNF-α. (PPTX 708 kb)
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